Varaico: Literature-Extracted Genetic Variants

Gene:PGM1
Variant:p.D263Y
Back to variants list

PGM1

NM_002633.3:p.D263Y

Associated Papers

Outcome of creatine supplementation therapy in phosphoglucomutase-1 deficiency associated congenital disorders of glycosylation: Novel insights.

Ambrose A et al.

Molecular Genetics and Metabolism Reports, 2025

Complex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in PGM1 and NDUFA13.

Radenkovic S et al.

Cells, 2025

40358162 (PubMed )
Supplement: cells-14-00638-s001.zip › cells-3567913-supplementary.pdf

Genetic landscape of primary mitochondrial diseases in children and adults using molecular genetics and genomic investigations of mitochondrial and nuclear genome.

Ambrose A et al.

Orphanet Journal of Rare Diseases, 2024

39533303 (PubMed )
Supplement: 13023_2024_3437_MOESM9_ESM.xlsx › Nuclear

Coagulation abnormalities and vascular complications are common in PGM1-CDG.

Radenkovic S et al.

Molecular Genetics and Metabolism, 2024

38968673 (PubMed )
Supplement: NIHMS2125712-supplement-Supplementary_material.xlsx › Sup_Tab_1

AAV-based gene therapy prevents and halts the progression of dilated cardiomyopathy in a mouse model of phosphoglucomutase 1 deficiency (PGM1-CDG).

Balakrishnan B et al.

Translational Research : the Journal of Laboratory and Clinical Medicine, 2023

N-Glycosylation influences human corticosteroid-binding globulin measurements.

Hill LA et al.

Endocrine Connections, 2019

Congenital disorder of glycosylation type 1T with a novel truncated homozygous mutation in PGM1 gene and literature review.

Tian WT et al.

Neuromuscular Disorders : Nmd, 2019

Central nervous involvement is common in PGM1-CDG.

Radenkovic S et al.

Molecular Genetics and Metabolism, 2018

Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency.

Abu Bakar N et al.

Translational Research : the Journal of Laboratory and Clinical Medicine, 2018

Mechanistic Insights on Human Phosphoglucomutase Revealed by Transition Path Sampling and Molecular Dynamics Calculations.

Brás NF et al.

Chemistry (weinheim an Der Bergstrasse, Germany), 2018

Oral D-galactose supplementation in PGM1-CDG.

Wong SY et al.

Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017

Asp263 missense variants perturb the active site of human phosphoglucomutase 1.

Stiers KM et al.

The Febs Journal, 2017

Sequence-structure relationships, expression profiles, and disease-associated mutations in the paralogs of phosphoglucomutase 1.

Muenks AG et al.

Plos One, 2017

Defining the Phenotype and Assessing Severity in Phosphoglucomutase-1 Deficiency.

Wong SY et al.

The Journal of Pediatrics, 2016

Induced Structural Disorder as a Molecular Mechanism for Enzyme Dysfunction in Phosphoglucomutase 1 Deficiency.

Stiers KM et al.

Journal of Molecular Biology, 2016

Mutations in hereditary phosphoglucomutase 1 deficiency map to key regions of enzyme structure and function.

Beamer LJ

Journal of Inherited Metabolic Disease, 2015

Compromised catalysis and potential folding defects in in vitro studies of missense mutants associated with hereditary phosphoglucomutase 1 deficiency.

Lee Y et al.

The Journal of Biological Chemistry, 2014

Novel insights into the phenotype and long-term D-gal treatment in PGM1-CDG: a case series.

Radenkovic S et al.

Therapeutic Advances in Rare Disease, 0

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."